Literature DB >> 12643180

Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion.

Richard E Pratley1, Christian Weyer.   

Abstract

Impaired glucose tolerance (IGT) is characterized by plasma glucose responses to an oral glucose challenge that are above normal but not at the level defining diabetes. IGT is a common condition that greatly increases risk for the subsequent development of type 2 diabetes. Individuals with IGT manifest abnormalities in both insulin action and early insulin secretion similar to those seen in patients with type 2 diabetes. These abnormalities not only precede diabetes, they predict it as well. Furthermore, the progression from IGT to diabetes is characterized by a dramatic decline in early insulin secretion. It is now evident that early insulin secretion plays an important role in the rapid and efficient suppression of endogenous glucose production following a meal. Loss of early insulin secretion initially leads to postprandial hyperglycemia which, as the disease progresses, worsens to clinical hyperglycemia. Obesity and a high fat diet may contribute to the development of both insulin resistance and insulin secretory dysfunction in susceptible individuals. Strategies that improve insulin resistance and enhance early insulin secretion may prevent the progression from IGT to diabetes. Already, there is substantial evidence the weight loss and exercise may reduce the risk of developing diabetes by up to 58%. Other trials using pharmacologic agents to decrease insulin resistance and increase early insulin secretion are underway. Prevention remains the best hope for a long-term solutions to the worldwide epidemic of diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12643180     DOI: 10.1007/s11892-002-0090-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  55 in total

1.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

Review 2.  Aspects of the pathogenesis of type 2 diabetes.

Authors:  S Efendić; R Luft; A Wajngot
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

3.  Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity.

Authors:  Y Harano; S Ohgaku; H Hidaka; K Haneda; R Kikkawa; Y Shigeta; H Abe
Journal:  J Clin Endocrinol Metab       Date:  1977-11       Impact factor: 5.958

4.  Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight.

Authors:  C Weyer; K Hanson; C Bogardus; R E Pratley
Journal:  Diabetologia       Date:  2000-01       Impact factor: 10.122

Review 5.  The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus.

Authors:  R E Pratley; C Weyer
Journal:  Diabetologia       Date:  2001-08       Impact factor: 10.122

6.  Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins.

Authors:  M Lehtovirta; J Kaprio; C Forsblom; J Eriksson; J Tuomilehto; L Groop
Journal:  Diabetologia       Date:  2000-03       Impact factor: 10.122

7.  Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.

Authors:  G Paolisso; M R Tagliamonte; M R Rizzo; P Gualdiero; F Saccomanno; A Gambardella; D Giugliano; F D'Onofrio; B V Howard
Journal:  Diabetologia       Date:  1998-10       Impact factor: 10.122

8.  Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

Authors:  B C Martin; J H Warram; A S Krolewski; R N Bergman; J S Soeldner; C R Kahn
Journal:  Lancet       Date:  1992-10-17       Impact factor: 79.321

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  A two-step model for development of non-insulin-dependent diabetes.

Authors:  M F Saad; W C Knowler; D J Pettitt; R G Nelson; M A Charles; P H Bennett
Journal:  Am J Med       Date:  1991-02       Impact factor: 4.965

View more
  14 in total

1.  A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents.

Authors:  C W Lin; J H Warram; P Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-11       Impact factor: 2.745

2.  A dietary pattern protective against type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)--Potsdam Study cohort.

Authors:  C Heidemann; K Hoffmann; J Spranger; K Klipstein-Grobusch; M Möhlig; A F H Pfeiffer; H Boeing
Journal:  Diabetologia       Date:  2005-05-12       Impact factor: 10.122

3.  Association between triclocarban and triclosan exposures and the risks of type 2 diabetes mellitus and impaired glucose tolerance in the National Health and Nutrition Examination Survey (NHANES 2013-2014).

Authors:  Xin Xie; Congying Lu; Min Wu; Jiayu Liang; Yuting Ying; Kailiang Liu; Xiuxia Huang; Shaoling Zheng; Xiuben Du; Dandan Liu; Zihao Wen; Guang Hao; Guang Yang; Liping Feng; Chunxia Jing
Journal:  Environ Int       Date:  2020-01-06       Impact factor: 9.621

4.  Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans.

Authors:  Mohammed Bensellam; Yan-Chuan Shi; Jeng Yie Chan; D Ross Laybutt; Heeyoung Chae; Michel Abou-Samra; Evan G Pappas; Helen E Thomas; Patrick Gilon; Jean-Christophe Jonas
Journal:  Diabetologia       Date:  2019-10-17       Impact factor: 10.122

5.  High glucose predisposes gene expression and ERK phosphorylation to apoptosis and impaired glucose-stimulated insulin secretion via the cytoskeleton.

Authors:  Ronne Wee Yeh Yeo; Kaiyuan Yang; GuoDong Li; Sai Kiang Lim
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

6.  A clinical evaluation of skin tags in relation to obesity, type 2 diabetis mellitus, age, and sex.

Authors:  Omar Soliman El Safoury; Magdy Ibrahim
Journal:  Indian J Dermatol       Date:  2011-07       Impact factor: 1.494

7.  NOD1 activators link innate immunity to insulin resistance.

Authors:  Jonathan D Schertzer; Akhilesh K Tamrakar; Joao G Magalhães; Sandra Pereira; Philip J Bilan; Morgan D Fullerton; Zhi Liu; Gregory R Steinberg; Adria Giacca; Dana J Philpott; Amira Klip
Journal:  Diabetes       Date:  2011-06-29       Impact factor: 9.461

8.  Strawberry and cranberry polyphenols improve insulin sensitivity in insulin-resistant, non-diabetic adults: a parallel, double-blind, controlled and randomised clinical trial.

Authors:  Martine Paquette; Ana S Medina Larqué; S J Weisnagel; Yves Desjardins; Julie Marois; Geneviève Pilon; Stéphanie Dudonné; André Marette; Hélène Jacques
Journal:  Br J Nutr       Date:  2017-03-14       Impact factor: 3.718

9.  Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.

Authors:  Christian Anholm; Preman Kumarathurai; Anders Jürs; Lene Rørholm Pedersen; Olav Wendelboe Nielsen; Ole Peter Kristiansen; Mogens Fenger; Jens Juul Holst; Sten Madsbad; Ahmad Sajadieh; Steen Bendix Haugaard
Journal:  Diabetol Metab Syndr       Date:  2019-05-31       Impact factor: 3.320

10.  Vitamin D supplementation for the prevention of type 2 diabetes in overweight adults: study protocol for a randomized controlled trial.

Authors:  Barbora de Courten; Aya Mousa; Negar Naderpoor; Helena Teede; Maximilian P J de Courten; Robert Scragg
Journal:  Trials       Date:  2015-08-07       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.